We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologousallogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by two gray TBI non-myeloablative conditioning. All patients received a first HDT as frontline treatment. At day 100 post allo-SCT, complete donor chimerism was detected in 22 patients (95%). Acute GVHD was observed in 19 patients (15 grade I-II (65%) and 4 grade III-IV (17%)). Ten patients (43%) developed an extensive chronic GVHD. The non-relapse mortality at 1 year was 17%. After TT, the overall response rate was 91% (17% partial response, 35% very good partial remission and 39% complete remission). At 2 years, OS was 61%. Median event-free survival and OS were 36.8 and 60 months, respectively. Based on the propensity score matching method, a significant survival advantage could be seen in patients treated with TT as compared with non-allografted patients. Thus, allo-SCT, in TT approach, provides a high response rate with low toxicity and may improve survival of patients with relapsing MM.
Introduction
Despite recent advances such as high dose therapy (HDT) followed by auto-SCT and novel therapies including proteasome inhibitors and immuno-modulatory drugs, multiple myeloma (MM) remains an incurable disease with a median survival of approximately 6 years. 1 Successive relapses with increasing resistance to chemotherapy and aggressive features occur and lead to a grim prognosis. Therefore, allo-SCT has been considered as a therapeutic alternative to improve survival by a graft versus myeloma effect. 2, 3 Allo-SCT with conventional myeloablative allografting has been mostly abandoned due to excessive TRM. 4, 5 Thus, non myeloablative (NMA) and reduced intensity conditioning allogeneic transplantation have been studied as treatment options in MM patients. Some randomized trials have evaluated the interest of adding allogeneic NMA transplantation to auto-SCT with conflicting results. [6] [7] [8] Similarly, series evaluating its interest and feasibility in relapsing patients are few and remain controversial. 9, 10 With the aim to better evaluate the role of NMA allograft in relapsing MM patients, we retrospectively studied a series of 23 MM relapsing patients who underwent NMA conditioning allograft according to a sequential autologous-allogeneic tandem approach and compared their outcome to that of a group of relapsing patients treated similarly in frontline, but who were not allografted at relapse. To reduce potential selection bias in the estimation of treatment effects using such observational data, we used the Propensity Score (PS) matching method as statistical analysis. Our results showed a significant benefit in survival for allografted patients as compared with non allografted patients.
Patients and methods

Treatment plan
Between October 2002 and August 2006, 23 consecutive MM patients in first or second relapse received a NMA tandem allograft at Saint-Louis Hospital, Paris, France. At the time of allogeneic transplantation, all patients were under 60 years of age. They were treated according to a sequential autologous-allogeneic tandem approach as previously described by the Seattle team. 11 Briefly, patients in first (n ¼ 21) or second (n ¼ 2) relapse received a treatment with either conventional therapy (VAD or alkylating agent-containing regimen) or new drugs (immuno-modulatory drugs and/or proteasome inhibitorcontaining regimen). Then, high dose melphalan (200 mg/ m 2 ) followed by auto-SCT was performed, followed in the next 2 months by NMA allograft. NMA conditioning consisted of 2 Grays TBI. Prophylaxis of GVHD consisted in the administration of oral cyclosporine and mycophenolate mofetil.
Patients
For each patient, the following data were recorded at diagnosis: demographics (age, gender), biologics (Hb level, level and type of serum paraprotein and urinary light chains, serum level of calcium, creatinine and b2 microglobulin (b2 m), percentage of bone marrow plasma cell infiltration, and cytogenetics when evaluable), radiological (lytic and/or condensate) lesions in bone radiographs and spinal magnetic resonance imaging (MRI)). Stage was assessed according to the Durie-Salmon's classification.
Relapse or progression was defined according to the IMWG criteria, 12 after partial response (PR) by more than 25% increase in the concentration of serum monoclonal component (which must also be greater than 5 g/L) and/or by a more than 50% increase in the concentration of urinary light chains, and/or by increasing associated symptoms (plasmacytomas, lytic bone lesions, hypercalcemia, renal insufficiency) and after complete response (CR), by reappearance of monoclonal protein and/or of associated symptoms. The following data were also recorded after the end of the first induction treatment: biological (level of serum paraprotein and urinary light chains, serum level of calcium and creatinine), and radiological (presence of lytic and/or condensate lesions in bone radiographs and spinal MRI) data.
Assessment of response
Treatment response was evaluated according to the IMWG criteria, 12 after first induction therapy, and at the time of relapse before the tandem autologous SCT, before allogeneic transplantation and within 6 months following completion of the procedure. A CR was defined by the absence of detectable monoclonal component in serum and urine by immunofixation. A very good partial response (VGPR) was defined by a more than 90% decrease of monoclonal component level in serum and urine. PR was defined by reduction comprised between 50 and 90% of the monoclonal component in both serum and urinary samples. Treatment failure was defined by a less than 50% decrease of monoclonal component in both serum and urinary samples.
Study end points
The primary end points were evaluation of response rate, EFS and OS following completion of the complete tandem procedure. We also assessed engraftment, chimerism, acute and chronic GVHD, and TRM. Response rate and EFS were also assessed after retreatment for post tandem relapses.
Statistical analysis
OS from the date of allograft until the date of death and EFS from the date of allograft until the date of disease progression were estimated according to the Kaplan-Meyer method.
Owing to these non-randomized available data, there was a need to correct for potential recruitment bias. The propensity score methodology allows coping with the presence of such a bias. The PS is defined as a subject's probability of receiving a specific treatment assignment conditional on the observed covariates. 13 Thus, we modeled through logistic regression, in patients with MM alive at 6 months after relapse, the probability of receiving NMA transplantation, conditional on a set of baseline characteristics (namely, baseline age, serum b2M, and RFS after the end of first induction treatment). Estimated odds ratio (OR) with 95% confidence intervals (95% CI) were computed. The estimated PS was then used to match 1:1 patients with similar propensity to receive allograft based on nearest neighbor matching using calipers of width 0.2. Data of patients treated in the MAG-95 and MAG-2002 trials were used.
14 Standardized differences in covariates between subjects in the matched sample were computed, with imbalances tested by paired t-tests. A random effects model was finally fitted to account for the matched nature of the data.
Results
Patients' characteristics at diagnosis of MM Clinical and biological characteristics of the 23 patients at diagnosis are reported in Table 1 . There were 11 men and 12 women. Median age was 48 years (range, 26-56 years). All patients presented with stage III MM except the one who presented with stage II. Isotype was IgG in 15 (65%) patients, IgA in four (17%) and light chain in four patients (17%). Median serum paraprotein level was 27.6 g/L (range, 3.6-109 g/L) and median urinary light chain level was 1.73 g/L (range, 1.22-22 g/L). Three patients presented 
First line therapy
Induction treatment consisted in 3 or 4 cycles of VAD (vincristine, adriamycin and dexamethasone) in 22 patients and in a 3-month combination of thalidomide and dexamethasone in 1. All patients received first line intensification with HDT followed by auto-SCT (melphalan (MLP) 200 mg/m 2 conditioning in 13 patients, melphalan 140 mg/m 2 plus TBI conditioning in four patients, melphalan 140 mg/m 2 conditioning in two and double auto-SCT in four patients) ( Table 2 ). Response rate after first line therapy is illustrated in Table 2 . Four (17%) patients were in CR, 11 (48%) in VGPR, and eight (35%) in PR. All patients responded to first line induction.
Patients relapsed with a median RFS of 15.8 months (range, 2.4-82.5 months) after the first auto-SCT. At relapse, median serum paraprotein level was 14 g/L (range, 2.7-120 g/L) and median urinary light chain level was 0.26 g/L (range, 0-13 g/L). No patient presented with renal insufficiency, one with hypercalcemia and one presented with circulating plasma cells. Eight patients had new lytic lesions or bone plasmacytomas (Table 3) . Two patients had a late first relapse and were included in the transplant program after the second relapse.
Treatment of relapse before tandem transplantation
The treatment of relapse before NMA allograft is detailed in Table 3 . Before the tandem transplant, 18 (78%) patients were treated with bortezomib or thalidomide containing regimen, whereas three (13%) were treated with alkylating agents and two (9%) were treated with VAD regimen. In all cases, the new auto-SCT was conditioned with melphalan 200 mg/m 2 .
Response rates before and after second HDT are illustrated in Table 3 . Before second HDT, no patient reached CR, 10 (43%) were in VGPR, 11 (48%) were in PR and two (9%) were in failure. After second HDT, CR, VGPR and PR were observed in four (17%), 10 (43%) and seven (30%) patients, respectively and two (9%) were in failure.
Engraftment and chimerism after allogeneic transplantation
Among the 23 patients, 13 were treated from HLAidentical siblings and 10 were treated from HLA-matched (10/10) unrelated donors. The median CD34 þ cell number infused was 6.85 Â 10 6 /kg body weight (range, 2.38-20.53). Only seven patients became neutropenic (o0.5 Â 10 9 /L) with a median length of neutropenia of 6 days (range, 3-14 days) requiring granulocyte colony-stimulating factor (G-CSF) injections in six cases. Only one patient became thrombocytopenic (o20 Â 10 9 /L) requiring platelet transfusion but without any severe hemorrhage. No primary or secondary graft failure was observed. All patients had achieved full donor chimerism in the first 3 months post allogeneic transplantation except the one who had partial chimerism.
Toxicity and GVHD
Apart from GVHD, no case of severe organ toxicity was observed except in one patient who presented resolutive hemorrhagic cystitis in the days following conditioning and heart failure 6 months after allograft. Severe infection developed in six patients, and were lethal in three (one died at 2 months from acute respiratory distress syndrome secondary to bacterial pneumonia, the second one died at 6 months from acute pancreatitis secondary to severe bacterial infection and the third one died at 8 months from severe infections pneumonia of unknown origin); two had adenovirus infection, one had invasive pulmonary Abbreviations: RFS=relapse-free survival; RR=response rate.
Non myeloablative allograft in multiple myeloma L Karlin et al aspergillosis and one had genital human papilloma virus infection, resolutive in all cases. CMV reactivation was documented in 10 patients (CMV infection in eight and CMV disease in two) resolutive in all cases with antiviral treatment. One patient died at 2 months from progressive disease. Four patients (17%) did not show any signs of acute GVHD. Three patients (13%) developed mild acute GVHD grade I; grade II was observed in 12 patients (52%). Grade III GVHD occurred in four patients (17%), and was lethal in one case. All patients transplanted with unrelated donors (n ¼ 10) developed an acute GVHD including 80% of grade I-II and 20% of grade III-IV.
Chronic GVHD was evaluable in 19 patients. Two patients (10%) developed limited chronic GVHD whereas an extensive chronic GVHD was observed in 10 (53%). In patients transplanted with unrelated donors, a chronic GVHD was observed in six cases including one patient with limited GVHD and five with extensive GVHD (Table 4) .
Response and survival after NMA allograft
The median time between allograft and the first relapse was 10.2 months (range, 8.2-18.8 months). The response rate 3 months after allograft is detailed in Table 4 . Nine (39%) patients had CR, eight (35%) had VGPR, four (17%) had PR and two (9%) were in failure. Two patients with PR and three patients with VGPR before allogeneic transplantation converted to CR after allografting. One patient with PR before allogeneic transplantation converted to VGPR after allografting. Patients in failure before allogeneic transplantation did not convert to a better response after allografting. In the subgroup of patients transplanted with unrelated donors (n ¼ 10), overall response was 90% including 30% of complete response and 40% of VGPR. Considering the 23 patients, the TRM at 1 year was 17% (four patients died, one from severe acute GVHD, three from severe infection). One patient died from PD at 2 months after allografting.
The median follow-up after the tandem procedure was 27.4 months (range, 1.8-61.8 months). At the time of statistical analysis, 14 (61%) patients were alive, including eight (35%) patients alive without relapse (Figure 1 ). Among those, five were in CR and three in VGPR.
The median post-allograft EFS was 36.8 months (Figure 2 ) and the median post-allograft OS exceeded 60 months (Figure 3) . Comparison of EFS after first auto-SCT and post allogeneic transplantation shows that among the eight patients without relapse after NMA allograft, five had reached significant longer EFS after the tandem procedure To evaluate the effect of non myeloablative allogeneic transplantation, the outcome of the transplant group was compared with a control group of patients not treated with allogeneic transplantation and matched on age and serum b2-microglobulin level. The median survival from diagnosis was estimated at 67.3 months (95% CI: 54.5-79.5) in nontransplant group as compared with 119.6 (95% CI: 109.2-NA) in the transplant group. To avoid bias due to patient's selection, the survival of the two groups was analyzed using the propensity score approach in patients alive at 6 months post relapse. A propensity score was derived from fitting a multivariate logistic model incorporating patient age at diagnosis (OR ¼ 0.90, 95% CI: 0.84-0.96), b2 microglobulin level X3.5 (OR ¼ 0.34, 95% CI: 0.11-1.12), and time elapsed since the first line treatment at relapse (OR ¼ 0.961, 95% CI: 0.928-0.995). Note that all the three were associated with a decrease in the propensity of being allografted. Then, a matched data set was constituted from the 21 patients who were successfully matched to one of the 142 available controls. The differences in covariates in the matched data set were erased, as expected. Based on these matched pairs, the estimated hazard ratio of death was 0.35 (95% confidence interval: 0.14-0.88, P ¼ 0.027) for allografted compared with non allografted patients (Figure 3 ).
Post allograft relapses
At the time of statistical analysis, 10 patients (41.6%) relapsed with a median of 10.7 months. Among those, seven were retreated: five with a combination of lenalidomide and dexamethasone, one with a combination of thalidomide and dexamethasone and one with a combination of bortezomib and dexamethasone. It is noteworthy that, six were still alive and three achieved a durable CR or VGPR. No donor lymphocyte infusions (DLI) were performed.
Discussion
This retrospective study of 23 relapsing MM patients shows that NMA allograft in first or second relapse is a feasible and effective treatment. With a 2-year OS of 61%, a median EFS post-allograft of 36.8 months and a median OS post-allograft reaching 5 years, it appears to be a promising therapeutic approach. In addition, long-term remissions of several years were observed in patients who presented with early relapse after first auto-SCT (median time: 15.8 months), reflecting a particularly aggressive disease. Moreover, according to our statistical analysis based on the propensity score matching method that control for confounding by adjusting for the likelihood that a given patient has received the new treatment, a significant survival advantage was observed for allografted MM patients as compared with non-allografted ones. This effect was associated with a low toxicity rate, especially a low TRM in the first year rate, which does not exceed 17%, similar to previously reported data. 15 In several patients, partial responses were converted to complete response after NMA allograft that appears therefore to be an efficient regimen in this disease. Therefore, the autologous-allogeneic tandem approach seems to be a well-adapted procedure without any problem of engraftment failure and with acceptable toxicity. This contrast to results reported after standard myeloablative conditioning approach associated with very high mortality rate in MM patients who are particularly vulnerable to infections and to renal complications. 4, 5 There is still some debate concerning the best time to propose allogeneic transplantation. In the recent randomized Italian study by Bruno et al. NMA allogeneic SCT was proposed to MM patients having an HLA-identical sibling donor using a similar tandem approach or a double autologous transplantation. 7 Although this study showed a significant improvement in terms of quality of response and OS, those results remain controversial because of a limited follow-up and a particularly low rate of response after the double autologous SCT. Moreover, a recent Spanish study and a previous IFM study failed to show a significant advantage of allogeneic approach as compared with autologous transplantation. 6, 8 The IFM study has been recently updated and long term follow-up even shows an advantage in the autologous transplantation arm. 16 In our experience, allogeneic transplantation as first line treatment was not considered since there are long-term survivors after autologous transplantation with minimal toxicity.
14 In contrast, it does not seem reasonable to propose allogeneic SCT after multiple relapses or lines of therapy because of a much higher risk of toxicity. Thus, first or second relapse seems to represent, for us, the right moment in the evolution of MM to propose this approach.
The rationale of allogeneic SCT is based on the possible graft versus myeloma effect. 2, 3, 17 In our series, we observed Non myeloablative allograft in multiple myeloma L Karlin et al a low rate of acute or chronic GVHD. However, we did not find any correlation between the existence of GVHD and response rate and survival. In contrast, in the 10 patients treated with non-related donors, the overall response rate was high and was associated with a high frequency of GVHD. The number of patients we treated precludes definitive conclusions and need to be increased in a larger study. It is interesting to note that, however, we found (as others) a synergistic effect in the allogeneic procedure and the use of new drugs such as immunomodulatory agents which could represent an effective way to improve and maintain response or to treat post tandem relapses. 18, 19 We have little experience in using DLI for the treatment of post allograft relapses in MM, but previous studies suggested an interesting effect of DLI in this context, especially in combination with novel drugs too. 20 This approach should be further evaluated in prospective trials.
Our study has some limits. Especially, we could argue that candidates for allograft were selected and that only slowly progressive diseases were allografted because the study was non-randomized. In addition, the longer OS observed in the transplant group as compared with the agematched non transplant group could be due to the fact that only patients surviving until relapse were considered in this study. However, by estimating the PS in patients alive after 6 months after relapse and analyzing the data within homogeneous levels of PS, in theory one can achieve a virtual randomization, in which comparable patients are separated into the exposed and unexposed groups. Moreover, in our series, a significant number of patients were allografted while they had a very short RFS after first autologous transplantation. Nevertheless, matching on propensity scores leads to unbiased estimation of treatment effects when certain assumptions hold, notably that all confounding covariates are observed. This supposes that no other covariates than age, b2 microglobulin level and time since first line therapy summarize all information affecting treatment decision.
We did not incorporate cytogenetics information and this should be questionable. However, no patients in this series had a t(4;14) known to be associated with a grim prognosis. 21 Besides, some preliminary recent data plaid for an improvement of prognosis of t(4;14) MM after allogeneic SCT. 22 Because of these encouraging results, we now propose allografting to all patients under 60 years of age in first or second relapse and having an HLA-identical sibling donor or a 10/10 allelic matched unrelated donor, except for those with a particularly long RFS after first autologous transplantation who are candidates for a new autologous transplantation or novel drug combination approach.
In conclusion, allogeneic transplantation in a tandem approach in relapsing MM patients seems to be a feasible and promising therapeutic option. This must be confirmed, however, in an ongoing multicenter prospective trial.
